ICON Reports First Quarter 2014

  • Quarter 1 net revenue increased 10% year on year to $350 million.
  • Income from operations was $43.0 million or 12.3% of revenue.
  • Earnings per share were 57 cents.
  • Gross Business wins were $494 million, representing a gross book to bill of 1.41, Net business wins were $427 million, representing a net book to bill of 1.22
  • FY 2014 Guidance updated: Revenue in the range of $1,480 million - $1,540 million and EPS in the range of $2.30 - $2.40.
DUBLIN--ICON plc(NASDAQ:ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the first quarter ended March 31, 2014.

For the first quarter, net revenue grew 10% year on year to $349.6 million from $316.8 million in Q1 2013.

Income from operations, excluding restructuring and other items, was $43.0 million or 12.3% of revenue, compared to $27.4 million or 8.7% for the same quarter last year.

Net income, excluding restructuring and other items, was $36.2 million or 57 cents per share on a diluted basis, compared with $22.2 million or 36 cents per share for the same quarter last year.

Guidance for the full year 2014 has been updated with revenue expected to be in the range of $1.48 billion - $1.54 billion and EPS guidance in the range of $2.30 - $2.40.

Days sales outstanding, comprising accounts receivable and unbilled revenue less payments on account, were 35 days at March 31, 2014, compared with 32 days at the end of December 2013.

For the quarter ended March 31, 2014, cash generated from operating activities was $38.7 million and capital expenditure was $6.2 million. The company's net cash amounted to $364 million at March 31, 2014, compared to net cash of $321 million at December 31, 2013.

CEO Ciaran Murray commented, "We have made an encouraging start to 2014. Revenue for Q1 increased 10% year on year and we continue to make good progress in expanding our operating margins which reached 12.3% in the quarter. The $427 million in net new business that we reported represents a book to bill of 1.22 and gives us a solid foundation upon which to build during the remainder of 2014. In addition in the quarter we have agreed to acquire Aptiv Solutions, a leader in the design and execution of adaptive and medical device trials. As a consequence of this acquisition and our continuing margin progression we are updating our full year 2014 guidance to revenue in the range of $1,480 - $1,540 and EPS in the range of $2.30 - $2.40."

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), this press release contains certain non-GAAP financial measures, including non-GAAP operating and net income and non-GAAP diluted earnings per share. While non-GAAP financial measures are not superior to or a substitute for the comparable GAAP measures, ICON believes certain non-GAAP information is useful to investors for historical comparison purposes.

ICON will hold its first quarter conference call today, April 30, 2014 at 9:00 EST [14:00 Ireland & UK]. This call and linked slide presentation can be accessed live from our website at http://investor.iconplc.com. A recording will also be available on the website for 90 days following the call. In addition, a calendar of company events, including upcoming conference presentations, is available on our website, under "Investors." This calendar will be updated regularly.

This press release contains forward-looking statements. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, as well as economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are available on the SEC's website at http://www.sec.gov.

ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 76 locations in 37 countries and has approximately 10,300 employees. Further information is available at www.iconplc.com.

ICON plc

 

Consolidated Income Statements (Unaudited)

(Before restructuring and other items)

 

Three Months ended March 31, 2014 and March 31, 2013

 

(Dollars, in thousands, except share and per share data)

 

 

 

Three Months Ended

    March 31,   March 31,
    2014   2013
         
Gross Revenue     476,544       419,059  
         
Reimbursable expenses     126,910       102,270  
         
Net Revenue     349,634       316,789  
         
Costs and expenses        
Direct Costs     216,140       202,361  
Selling, general and administrative     78,948       75,564  
Depreciation and amortisation     11,548       11,456  
         
Total costs and expenses     306,636       289,381  
         
Income from operations     42,998       27,408  
         
Net interest income / (expense)     91       (185 )
         
Income before provision for income taxes     43,089       27,223  
         
Provision for income taxes     (6,894 )     (5,021 )
         
         
Net Income     36,195       22,202  
         
Net income per ordinary share        
Basic   $ 0.59     $ 0.37  
         
Diluted   $ 0.57     $ 0.36  
         
Weighted average number of ordinary shares        
Basic     61,776,643       60,404,242  
         
Diluted     63,225,797       61,323,594  
 

 

ICON plc

 

Consolidated Income Statements (Unaudited)

(US GAAP)

 

Three Months ended March 31, 2014 and March 31, 2013

 

(Dollars, in thousands, except share and per share data)

 

 

 

Three Months Ended

    March 31,   March 31,
    2014   2013
         
Gross Revenue     476,544       419,059  
         
Reimbursable expenses     126,910       102,270  
         
Net Revenue     349,634       316,789  
         
Costs and expenses        
Direct costs     216,140       202,361  
Selling, general and administrative     78,948       75,564  
Depreciation and amortization     11,548       11,456  
Restructuring and other items     -       4,412  
         
Total costs and expenses     306,636       293,793  
         
Income from operations     42,998       22,996  
         
Net interest expense     91       (185 )
         
Income before provision for income taxes     43,089       22,811  
         
Provision for income taxes     (6,894 )     (3,766 )
         
         
Net income     36,195       19,045  
         
Net income per ordinary share        
Basic   $ 0.59     $ 0.32  
         
Diluted   $ 0.57     $ 0.31  
         
Weighted average number of ordinary shares        
Basic     61,776,643       60,404,242  
         
Diluted     63,225,797       61,323,594  
 

 

ICON plc

Summary Balance Sheet Data

March 31, 2014 and December 31, 2013

(Dollars, in thousands)

 
    March 31,   December 31,
    2014   2013
    (Unaudited)   (Audited)
         
         
Net cash   363,521     320,836  
         
Accounts receivable   337,600     342,581  
Unbilled revenue   116,653     113,239  
Payments on account   (269,771 )   (297,347 )
Total   184,482     158,473  
         
Working Capital   405,923     352,259  
         
Total Assets   1,484,541     1,442,460  
         
Shareholder's Equity   960,785     910,579  

ICON/ICLR-F

Contacts

ICON plc
Investor Relations, 1-888-381-7923
or
Brendan Brennan, +353-1-291-2000
CFO
Simon Holmes, +3531-291-2000
EVP IR & Corporate Development
http://www.iconplc.com

 

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.